ORIC Pharmaceuticals Inc(ORIC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 7:32 AM ET (Korea 10/29 20:32)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.35 | Insider Own | 34.19% | Shs Outstand | 103.6M | Perf Week | -32.85% |
| Market Cap | 0.96B | Forward P/E | - | EPS next Y | -11.12% | Insider Trans | -0.35% | Shs Float | 68.2M | Perf Month | -30.44% |
| Enterprise Value | 0.70B | PEG | - | EPS next Q | -0.39 | Inst Own | 86.98% | Short Float | 22.61% | Perf Quarter | -20.1% |
| Income | -0.14B | P/S | - | EPS this Y | -2.44% | Inst Trans | 6.81% | Short Ratio | 9.74 | Perf Half Y | -1.48% |
| Sales | 0.00B | P/B | 2.53 | EPS next 5Y | -7.08% | ROA | -37.35% | Short Interest | 15.42M | Perf YTD | 13.69% |
| Book/sh | 3.68 | P/C | 3.64 | EPS past 3/5Y | 13.1% 15.18% | ROE | -39.8% | 52W High | -36.65% ($14.68) | Perf Year | -30.75% |
| Cash/sh | 2.55 | P/FCF | - | Sales past 3/5Y | - | ROIC | -36.81% | 52W Low | 28.63% ($7.23) | Perf 3Y | 48.09% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 28.64% | Gross Margin | - | Volatility(W/M) | 15.2% 8.99% | Perf 5Y | -37.79% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.01 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.19 | EPS Q/Q | 17.45% | Profit Margin | - | RSI (14) | 31.9 | Recom | 1.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.19 | Sales Q/Q | - | SMA20 | -22.33% ($11.97) | Beta | 1.17 | Target Price | $21.71 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/3 | SMA50 | -26.58% ($12.67) | Rel Volume | 0.89 | Prev Close | $9 |
| Employees | 104 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -5.76% - | SMA200 | -16.63% ($11.16) | Avg Volume(3M) | 1.58M | Price | $9.3 |
| IPO | 2020/4/24 | Option/Short | Yes/Yes | Trades | 10568 | Volume | 1,414,050 | Change | 3.33% |
🧬 ORIC Pharmaceuticals (ORIC) is a clinical-stage oncology biotech company focused on overcoming drug resistance mechanisms in cancer treatment. Its precision oncology pipeline includes ORIC-944, a polycomb complex inhibitor, and enozertinib, a targeted kinase inhibitor, with prostate cancer and non-small cell lung cancer as the core indications under development.
Over the past 1 year, roughly in the middle
37% below its 1-year high.
Traded about as much as usual. That is 89% of its average volume.
ORIC has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -2.4% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -37.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
22.6% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #160 of 594 in the industry
Based on market cap of $964M.
PRME#159 Prime Medicine Inc $972M PER - ORIC#160 ORIC Pharmaceuticals Inc $964M PER - 
KURA#161 Kura Oncology Inc $954M PER - 
ALMS#162 Alumis Inc $952M PER - 
RIGL#163 Rigel Pharmaceuticals $948M PER 3.1 
FAQ
What kind of company is ORIC?
ORIC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ORIC?
The market cap of ORIC is approximately $964M, ranking 2,608 within its sector.
What is the 52-week high and low for ORIC?
ORIC has recorded a 52-week high of $14.68 and a low of $7.23.
